Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
- pharma
Copovidone K25-31
CAS 25086-89-9
Concern score
Not assessed — no hazard data yet.
Why it's flagged
Route: ORAL; Dosage form: CAPSULE; Maximum daily exposure: 1346 mg
Regulation
No restrictions found. Copovidone K25-31 appears in these published regulatory listings.
- definition_level:incomplete
- definition_type:primary
- inactive_ingredient_database
- ingredient_type:ingredient substance
- substance_class:polymer
- substance_type:polymer
USFDAinactive ingredient database16 entries — 3 administration routes
- Route: ORAL; Dosage form: CAPSULE; Maximum daily exposure: 1346 mgSource →
- Route: ORAL; Dosage form: CAPSULE, COATED PELLETS; Maximum daily exposure: 88 mgSource →
- Route: ORAL; Dosage form: CAPSULE, DELAYED RELEASE; Maximum daily exposure: 199 mgSource →
- Route: ORAL; Dosage form: CAPSULE, EXTENDED RELEASE; Maximum daily exposure: 200 mgSource →
- Route: ORAL; Dosage form: PELLET; Maximum daily exposure: 1653 mgSource →
- Route: ORAL; Dosage form: POWDER, FOR SUSPENSION; Maximum daily exposure: 5917 mgSource →
- Route: ORAL; Dosage form: SUSPENSION; Maximum daily exposure: 172 mgSource →
- Route: ORAL; Dosage form: TABLET; Maximum daily exposure: 6374 mgSource →
- Route: ORAL; Dosage form: TABLET, CHEWABLE; Maximum daily exposure: 5 mgSource →
- Route: ORAL; Dosage form: TABLET, DELAYED RELEASE; Maximum daily exposure: 168 mgSource →
- Route: ORAL; Dosage form: TABLET, EXTENDED RELEASE; Maximum daily exposure: 300 mgSource →
- Route: ORAL; Dosage form: TABLET, FILM COATED; Maximum daily exposure: 5917 mgSource →
- Route: ORAL; Dosage form: TABLET, FILM COATED, EXTENDED RELEASE; Maximum daily exposure: 53 mgSource →
- Route: ORAL; Dosage form: TABLET, ORALLY DISINTEGRATING; Maximum daily exposure: 35 mgSource →
- Route: SUBLINGUAL; Dosage form: TABLET; Maximum daily exposure: 54 mgSource →
- Route: TRANSDERMAL; Dosage form: FILM, EXTENDED RELEASE; Potency: NASource →
USFDAlisted in openFDA substanceopenFDA substance registry classifies this ingredient as polymer.
- openFDA substance registry classifies this ingredient as polymer.Source →
Evidence
No graded sources yet for Copovidone K25-31. We publish evidence only once a source is linked and reviewed — this ingredient is in the catalog, but has not been assessed.
Suitability
Context-specific fit derived from published classifications and the current ingredient evidence profile.
Good fit
